522 related articles for article (PubMed ID: 35966313)
21. Construction and validation of a prognostic model for stemness-related genes in lung adenocarcinoma.
Zhang H; Cao C; Xiong H
Transl Cancer Res; 2024 Mar; 13(3):1351-1366. PubMed ID: 38617509
[TBL] [Abstract][Full Text] [Related]
22. Identification of a circadian gene signature that predicts overall survival in lung adenocarcinoma.
Gao X; Tang M; Tian S; Li J; Liu W
PeerJ; 2021; 9():e11733. PubMed ID: 34285836
[TBL] [Abstract][Full Text] [Related]
23. Construction of a prognostic model for lung adenocarcinoma based on bioinformatics analysis of metabolic genes.
He J; Li W; Li Y; Liu G
Transl Cancer Res; 2020 May; 9(5):3518-3538. PubMed ID: 35117717
[TBL] [Abstract][Full Text] [Related]
24. A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer.
Zuo S; Wei M; Zhang H; Chen A; Wu J; Wei J; Dong J
J Transl Med; 2019 May; 17(1):152. PubMed ID: 31088477
[TBL] [Abstract][Full Text] [Related]
25. Identification of a necroptosis-related gene signature for making clinical predictions of the survival of patients with lung adenocarcinoma.
Zhou X; Zhao M; Fan Y; Xu Y
PeerJ; 2024; 12():e16616. PubMed ID: 38213773
[TBL] [Abstract][Full Text] [Related]
26. Development of metastasis-associated seven gene signature for predicting lung adenocarcinoma prognosis using single-cell RNA sequencing data.
He J; Zhang W; Li F; Yu Y
Math Biosci Eng; 2021 Jul; 18(5):5959-5977. PubMed ID: 34517518
[TBL] [Abstract][Full Text] [Related]
27. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
Front Immunol; 2022; 13():783495. PubMed ID: 35222371
[TBL] [Abstract][Full Text] [Related]
28. Competitive endogenous RNA network identifies four long non-coding RNA signature as a candidate prognostic biomarker for lung adenocarcinoma.
Hu J; Wang T; Chen Q
Transl Cancer Res; 2019 Aug; 8(4):1046-1064. PubMed ID: 35116848
[TBL] [Abstract][Full Text] [Related]
29. Integrative learning in developing an immunologic lncRNA signature as a consensus risk-stratification tool for lung adenocarcinoma.
Chen Z; Liu Y; Wan C; Huang W
J Thorac Dis; 2023 Apr; 15(4):1823-1837. PubMed ID: 37197549
[TBL] [Abstract][Full Text] [Related]
30. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
31. A novel ferroptosis-related genes model for prognosis prediction of lung adenocarcinoma.
Li F; Ge D; Sun SL
BMC Pulm Med; 2021 Jul; 21(1):229. PubMed ID: 34256754
[TBL] [Abstract][Full Text] [Related]
32. Construction of a prognostic model for lung adenocarcinoma based on membrane-tension-related genes.
Zhu P; Teng Z; Yang W; Zhang D; Wang B; Yang Z; Wang K; Pu J
J Thorac Dis; 2023 Apr; 15(4):2098-2115. PubMed ID: 37197492
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of pyroptosis-related factors in lung adenocarcinoma.
Lin X; Zhou T; Hu S; Yang L; Yang Z; Pang H; Zhou X; Zhong R; Fang X; Yu Z; Hu K
J Thorac Dis; 2022 Mar; 14(3):654-667. PubMed ID: 35399245
[TBL] [Abstract][Full Text] [Related]
34. DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management.
Ma X; Cheng J; Zhao P; Li L; Tao K; Chen H
J Cell Mol Med; 2020 Jul; 24(13):7576-7589. PubMed ID: 32530136
[TBL] [Abstract][Full Text] [Related]
35. Tumor necrosis factor-related lncRNAs predict prognosis and immunotherapy response for patients with lung adenocarcinoma.
Chen JH; Wu X; Wang ZM; Liu ZY; He BX; Song WP; Zhang WZ
J Thorac Dis; 2023 Mar; 15(3):1373-1386. PubMed ID: 37065578
[TBL] [Abstract][Full Text] [Related]
36. Establishment and validation of a prognostic signature for lung adenocarcinoma based on metabolism-related genes.
Wang Z; Embaye KS; Yang Q; Qin L; Zhang C; Liu L; Zhan X; Zhang F; Wang X; Qin S
Cancer Cell Int; 2021 Apr; 21(1):219. PubMed ID: 33858449
[TBL] [Abstract][Full Text] [Related]
37. Development and validation of a novel epigenetic-related prognostic signature and candidate drugs for patients with lung adenocarcinoma.
Wang Z; Embaye KS; Yang Q; Qin L; Zhang C; Liu L; Zhan X; Zhang F; Wang X; Qin S
Aging (Albany NY); 2021 Jul; 13(14):18701-18717. PubMed ID: 34285141
[TBL] [Abstract][Full Text] [Related]
38. Angiogenesis-related lncRNAs predict the prognosis signature of stomach adenocarcinoma.
Han C; Zhang C; Wang H; Li K; Zhao L
BMC Cancer; 2021 Dec; 21(1):1312. PubMed ID: 34876056
[TBL] [Abstract][Full Text] [Related]
39. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
Ma C; Li F; Gu Z; Yang Y; Qi Y
Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938
[No Abstract] [Full Text] [Related]
40. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
Wang H; Wei C; Pan P; Yuan F; Cheng J
Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
